Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Open-Label, Randomized, Albumin-Controlled, Parallel Group, Multicenter Study to Evaluate the Effect of Medium Molecule HES (130/0.4) in Complications for Patients After Abdominal Surgery

NCT00308126 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.

NCT NCT00308126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00308126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Open-Label, Randomized, Albumin-Controlled, Parallel Group, Multicenter Study to Evaluate the Effect of Medium Molecule HES (130/0.4) in Complications for Patients After Abdominal Surgery
Lead sponsor
Fresenius Kabi
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2005
Completion date
September 30, 2006
Enrollment
624
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postoperative complications